Magneto low-density nanoemulsion (MLDE): A potential vehicle for combined hyperthermia and photodynamic therapy to treat cancer selectively

Autor(es)

Pellosi, Diogo Silva ^{[1, 2]} ; Macaroff, Patricia Pereira ^[2] ; Morais, Paulo Cesar ^[3] ; Tedesco, Antonio Claudio ^[2]

Afiliação do(s) autor(es)

^[1] Univ Fed Selo Paulo UNIFESP, Lab Hibrid Mat, Dept Ciencias Exatas & Terra, Rua Sao Nicolau 210, BR-09913030 Diadema - Brazil

^[2] Univ Sao Paulo, Ctr Nanotechnol & Tissue Engn, Photobiol & Photomed Res Grp, Dept Chem, Fac Philosophy Sci & Letters Ribeirao P, Sao Paulo - Brazil

^[3] Univ Brasilia, Lab Opt Spect, Inst Phys, BR-70919970 Brasilia, DF - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Materials Science & Engineering C-Materials for Biological Applications; v. 92, p. 103-111, NOV 1 2018.
• Citações Web of Science: 4

Resumo

In this paper, we introduce a new drug delivery system (DDS) called magneto low-density nanoemulsion (MLDE), which can carry maghemite nanoparticles and Chlorin e6 as an active photosensitizer drug. This design can enhance tumor damage after minor heat dissipation and/or minimum visible light photosensitization doses by classical magnetic hyperthermia (MHT) and photodynamic therapy (PDT), respectively. We establish protocols to prepare the MLDE and to load the drug combination onto it. The MLDE prepared herein is nanometric ( < 200 nm), has high encapsulation efficiency, and is stable for at least 12 months in water dispersions. Flow cytometry results demonstrated that MLDE presents targeted selectivity toward the MCF-7 breast cancer cell line but not in NHI-3T3 mouse fibroblast cell lines, because the MCF-7 cancer cell surface contains overexpressed low density lipoprotein (LDL) receptors. Despite this targeted effect, MHT or PDT alone does not prompt significant antiproliferative outcomes. On the other hand, MHT and PDT in combination induce a strong and synergic action on MCF-7 cells and reduce the cell viability. In conclusion, the developed MLDE deserves further investigation because it is biocompatible, displays good encapsulation efficiency, and is highly stable. Moreover, it is selectively taken up by cancer cell surfaces with receptor recognition based on LDL receptor overexpression, which potentiates the action of combined MHT and PDT. (AU)

• Processo FAPESP: 15/18684-9 - Utilização de nanocarreadores contendo fármacos fotossensibilizantes e outros ativos aplicados à terapia celular e tratamento de patologias do sistema nervoso central
• Beneficiário: Leonardo Barcelos de Paula
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 16/00389-3 - Nanopartículas multifuncionais para a entrega sítio-específica da temozolomida® e verteporfina® para a terapia combinada de tumores cerebrais
• Beneficiário: Diogo Silva Pellosi
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 13/50181-1 - Utilização de nanocarreadores contendo fármacos fotossensibilizantes e outros ativos aplicados à terapia celular e tratamento de patologias do sistema nervoso central
• Beneficiário: Antonio Claudio Tedesco
• Modalidade de apoio: Auxílio à Pesquisa - Temático